As global insulin demand continues to rise, especially across low- and middle-income countries, access to treatment is not growing fast enough to meet the need.
Our new insulin market analysis reveals a critical gap: while the number of people receiving insulin in LMICs will more than double by 2035—from 35 million to 76 million—millions will still go without. Today, only 36% of the 95 million people who need insulin can get it. Even with treatment expansion, 30 million people will remain without access, with most progress concentrated in just a few regions.
This market memo explores the forces behind this uneven progress—from China’s shift toward GLP-1 therapies, signaling trends likely to emerge elsewhere, to persistent barriers in sub-Saharan Africa and South Asia. We look at how product fragmentation, diagnostic capacity, and health system readiness are shaping the market.
Read the full memo to understand where global insulin access is heading—and what it will take to ensure no one is left behind.
